查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1980617

大腸直腸癌篩檢市場規模、佔有率、成長和全球行業分析：按類型、應用和地區分類，並提供 2026-2034 年的洞察和預測。

Colorectal Cancer Screening Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 140 Pages | 商品交期: 請詢問到貨日

價格

大腸直腸癌篩檢（CRC）市場的成長要素

全球大腸直腸癌篩檢市場預計在2025年達到186.2億美元，2026年成長至194.2億美元，2034年達到276.9億美元，預測期內複合年成長率（CAGR）為4.50%。北美地區在2025年將佔據市場主導地位，市佔率高達65.04%，主要得益於較高的健康意識、早期篩檢計畫的推廣以及有利的保險報銷政策。大腸直腸癌（CRC）主要影響45歲及以上的成年人，早期篩檢能顯著改善治療效果。大腸直腸癌發生率的上升以及政府推廣篩檢的措施是推動市場成長的主要因素。

市場促進因素

大腸直腸癌發生率的上升是推動市場成長的主要因素。雖然已開發國家的發病率較高，但由於不健康的生活方式和人口老化，中低收入國家的病例數量也不斷增加。根據美國癌症協會2025年的報告，美國直腸癌和結腸癌病例數將分別達到46,950例和107,320例。此外，根據美國疾病管制與預防中心（CDC）的數據，2022年美國新增大腸直腸癌病例147,931例，2023年死亡病例53,779例。這些不斷上升的發病率和死亡率增加了對結直腸癌檢測的需求，預計將推動市場成長。

市場限制因素

儘管有強力的臨床證據支持，市場仍面臨許多限制因素。篩檢參與率低，尤其是在中低收入國家，阻礙了篩檢的廣泛普及。即使在已開發地區，恐懼、不適和認知不足也降低了篩檢率。大腸鏡檢查作為黃金標準，屬於侵入性檢查，需要腸道準備、鎮靜和專門的醫療設施，導致每次檢查費用高昂。糞便DNA檢測和血液檢測等新型檢測方法比糞便免疫化學檢查（FIT）更昂貴，這造成了獲取途徑的障礙，並限制了它們被納入公共醫療計畫。保險報銷的差異也加劇了全球篩選機會的不平等。

市場機遇

非侵入性居家大腸直腸癌篩檢 (CRC) 檢測正逐漸成為一項重要的商業機會。這些檢測，包括糞便免疫化學檢測 (FIT)、糞便大便潛血試驗(FOBT) 和多靶點糞便 DNA 檢測，消除了傳統檢測相關的風險，例如腸道清潔和不適感，並提高了無症狀人群和不願篩檢人群的篩檢率。 2024 年 7 月，Guardant Health 的 Shield 血液檢測獲得 FDA核准，這是首個針對 45 歲及以上成年人的篩檢檢測，符合 Medicare 的報銷條件。診斷試劑製造商、醫療服務提供者和公共衛生機構之間的合作正在推動居家檢測和數位化報告的普及，進一步提高了檢測依從性和複檢率。

市場挑戰

雖然大腸鏡檢查準確率高，但由於其有穿孔、出血、感染疾病和鎮靜劑相關併發症等風險，限制了其廣泛應用。美國國家生物技術資訊中心（NCBI）2025年的一項研究表明，65歲及以上成年人的結腸穿孔率和出血率分別為0.078%和0.235%，而80歲及以上人群的風險更高。隨著人們對這些風險的認知不斷提高，非侵入性糞便檢驗檢測和分子檢測的偏好逐漸增強，這限制了大腸鏡檢查的普及。

市場趨勢

市場正朝著侵入性更小、負擔更輕的診斷方法轉變。糞便檢驗擴大被用作篩檢，而大腸鏡檢查則通常用於確診。大腸鏡檢查的技術進步，例如高解析度成像、人工智慧輔助息肉檢測和一次性內視鏡，在提高診斷準確性的同時，也降低了感染風險。

細分分析

按類型：

  • 由於大腸鏡檢查準確率高，預計到 2026 年，大腸鏡檢查將佔據市場主導地位，佔總市場佔有率的 71.27%。
  • 糞便檢驗（包括 FIT、gFOBT 和糞便 DNA 檢測）預計將以 10.7% 的複合年成長率成長。

按最終用戶分類：

  • 到 2026 年，醫院和診所將佔全球市場的 53.04%，這主要得益於患者數量的龐大。
  • 預計在預測期內，臨床檢查室的複合年成長率將達到 6.4%。

區域展望

  • 北美：美國預計將在 2025 年（121.1 億美元）和 2026 年（126.4 億美元）佔據市場主導地位，2026 年美國將佔全球銷售額的 124.4 億美元（64%）。
  • 歐洲：預計到 2025 年將以 8.3% 的複合年成長率成長，達到 9 億美元。主要市場包括英國（2026 年為 1.7 億美元）和德國（2026 年為 4 億美元）。
  • 亞太地區：預計2025年將達到48.6億美元，其中日本佔5.7億美元（2026年），中國佔19.6億美元（2026年）。印度將貢獻17.1億美元（2026年）。
  • 拉丁美洲、中東和非洲：新興市場，包括沙烏地阿拉伯（到 2025 年將達到 1 億美元），由於宣傳活動的增加和篩檢測試的廣泛普及，正在擴大。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 大腸直腸癌發生率（2020 年）－主要國家，2025 年
  • 概述：大腸直腸癌篩檢計畫（主要國家）
  • 新產品核准
  • 概述：各組織在結直腸癌篩檢方面的公私合營和實施策略—主要國家
  • 主要國家進行的大腸直腸癌篩檢數量（2025 年）
  • 市面上檢測的平均價格
  • 關鍵產業趨勢（併購、合作）
  • 摘要：大腸鏡檢查超負荷的國家

第5章：2021-2034年全球大腸直腸癌篩檢市場分析、洞察與預測

  • 市場分析、洞察與預測：按類型
    • 糞便檢驗
      • 糞便免疫化學檢查（FIT）
      • 大便潛血試驗（FOBT）
      • 糞便DNA檢測
    • 大腸鏡檢查
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院和診所
    • 臨床檢查室
    • 診斷影像中心
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美大腸癌篩檢市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲大腸直腸癌篩檢市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區大腸直腸癌篩檢市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲結直腸癌篩檢市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲大腸直腸癌篩檢市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 2025年糞便檢驗市場企業市場占有率分析
  • 大腸鏡檢查企業市場占有率分析，2025 年
  • 公司簡介
    • NOVIGENIX SA
    • EIKEN CHEMICAL CO., LTD.
    • Clinical Genomics Technologies Pty Ltd.
    • Exact Sciences Corporation
    • Epigenomics AG
    • bioMerieux, Inc.
    • OLYMPUS CORPORATION
    • KARL STORZ SE & Co. KG
    • FUJIFILM Holdings America Corporation
Product Code: FBI101144

Growth Factors of colorectal cancer (CRC) screening Market

The global colorectal cancer (CRC) screening market was valued at USD 18.62 billion in 2025 and is projected to grow to USD 19.42 billion in 2026, reaching USD 27.69 billion by 2034, exhibiting a CAGR of 4.50% during the forecast period. North America dominated the market in 2025 with a 65.04% share, driven by high awareness, early detection programs, and favorable reimbursement policies. CRC primarily affects adults aged 45 and above, with early detection significantly improving treatment outcomes. The rising prevalence of colorectal cancer and government initiatives promoting screening are key drivers fueling market growth.

Market Drivers

The increasing incidence of colorectal cancer is a major market driver. Developed countries report higher incidence rates, while middle- and low-income countries are witnessing rising cases due to unhealthy lifestyles and aging populations. According to the American Cancer Society in 2025, rectal cancer and colon cancer cases in the U.S. were 46,950 and 107,320, respectively. Furthermore, the Centers for Disease Control and Prevention (CDC) reported 147,931 new colorectal cancer cases in the U.S. in 2022, with 53,779 deaths in 2023. This rising incidence and mortality have heightened the demand for CRC detection and are expected to propel market growth.

Market Restraints

Despite strong clinical rationale, the market faces significant restraints. Low screening participation, especially in low- and middle-income countries, limits adoption. Even in developed regions, fear, discomfort, and lack of awareness reduce screening uptake. Colonoscopy, the gold standard, is invasive, requires bowel preparation, sedation, and specialized infrastructure, driving up per-test costs. Emerging modalities like stool-DNA and blood-based tests are expensive compared to fecal immunochemical tests (FIT), restricting access and limiting public program inclusion. Reimbursement variability also contributes to uneven access globally.

Market Opportunities

Non-invasive and at-home CRC screening tests are emerging as substantial opportunities. These tests, such as FIT, fecal occult blood tests (FOBT), and multi-target stool DNA tests, eliminate procedural risks, bowel preparation, and discomfort, enhancing adoption among asymptomatic and screening-averse populations. In July 2024, Guardant Health received FDA approval for its Shield blood test as the first primary screening option for adults aged 45 and above, supporting Medicare reimbursement. Collaborations among diagnostics companies, healthcare providers, and public health agencies are enabling home testing and digital reporting, further increasing compliance and repeat testing rates.

Market Challenges

Colonoscopy, while accurate, carries procedural risks such as perforation, bleeding, infection, and sedation-related complications, limiting its uptake. A 2025 study published by NCBI indicated perforation and bleeding rates of 0.078% and 0.235%, respectively, among adults over 65, with higher risks in those over 80. Awareness of these risks is shifting preference toward non-invasive stool-based and molecular tests, restricting colonoscopy adoption.

Market Trends

The market is witnessing a shift toward less invasive, patient-friendly pathways. Stool-based tests are increasingly used as first-line screening, reserving colonoscopy for confirmation. Technological advancements in colonoscopy, such as high-definition imaging, AI-based polyp detection, and single-use endoscopes, are improving diagnostic yield while addressing infection risks.

Segmentation Analysis

By Type:

  • Colonoscopy dominated the market in 2026 with 71.27% share due to its high accuracy.
  • Stool-based tests are projected to grow at a CAGR of 10.7%, including FIT, gFOBT, and stool-DNA tests.

By End-User:

  • Hospitals & clinics held 53.04% of the global market in 2026, driven by high patient volumes.
  • Clinical laboratories are expected to grow at a CAGR of 6.4% during the forecast period.

Regional Outlook

  • North America: Dominated the market in 2025 (USD 12.11 billion) and 2026 (USD 12.64 billion), with the U.S. accounting for USD 12.44 billion in 2026 (64% of global revenues).
  • Europe: Projected to grow at CAGR 8.3%, valued at USD 0.90 billion in 2025. Key markets include the U.K. (USD 0.17 billion in 2026) and Germany (USD 0.40 billion in 2026).
  • Asia Pacific: Estimated at USD 4.86 billion in 2025, with Japan at USD 0.57 billion (2026) and China at USD 1.96 billion (2026). India contributes USD 1.71 billion (2026).
  • Latin America & Middle East & Africa: Emerging markets, including Saudi Arabia (USD 0.10 billion in 2025), are expanding due to awareness programs and increased availability of screening tests.

Competitive Landscape

Prominent players include Olympus Corporation, Exact Sciences Corporation, Quest Diagnostics, FUJIFILM Holdings, and Clinical Genomics Technologies, focusing on advanced colonoscopy and stool-based products. Recent developments include:

  • January 2025: NHS England rollout of home FIT screening.
  • August 2024: Guardant Health Shield blood test FDA-approved and Medicare-covered.
  • February 2024: Launch of ColoTest by Reese Pharmaceutical.
  • November 2023: Shield blood-based CRC test launched in South Korea.

Conclusion

The global colorectal cancer screening market is poised for steady growth, fueled by rising CRC incidence, technological innovations, and adoption of non-invasive and home-based screening tests. While colonoscopy remains the gold standard, non-invasive solutions are expanding access, improving compliance, and driving market expansion globally. By 2034, the market is expected to reach USD 27.69 billion, offering significant opportunities for diagnostic companies, healthcare providers, and public health agencies worldwide.

Segmentation By Type, End-user, and Region

By Type * Stool-based

    • Fecal Immunochemical Test (FIT)
    • Fecal Occult Blood Test (FOBT)
    • Stool-DNA Test
  • Colonoscopy
  • Others

By End-user

Hospitals & Clinics

  • Clinical Laboratories
  • Diagnostic Imaging Centers
  • Others

By Region * North America (By Type, End-user, and Country)

    • U.S.
    • Canada
  • Europe (By Type, End-user, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, End-user, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, End-user, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, End-user, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence of Colorectal Cancer (2020) - For Key Countries, 2025
  • 4.2. Overview : Colorectal Cancer Screening Programs (Key Countries/ Regions)
  • 4.3. New Product Approvals
  • 4.4. Overview: Public Private Partnerships, Strategies Implemented by Organizations for Colorectal Cancer Screening - Key Countries
  • 4.5. Number of Colorectal Cancer Screening Procedures - For Key Countries, 2025
  • 4.6. Average Prices of the Tests in the Market
  • 4.7. Key Industry Developments (Mergers, Acquisitions, Partnerships)
  • 4.8. Overview : Countries with Overburden of Colonoscopies

5. Global Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Stool-based
      • 5.1.1.1. Fecal Immunochemical Test (FIT)
      • 5.1.1.2. Fecal Occult Blood Test (FOBT)
      • 5.1.1.3. Stool-DNA Test
    • 5.1.2. Colonoscopy
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By End-user
    • 5.2.1. Hospitals & Clinics
    • 5.2.2. Clinical Laboratories
    • 5.2.3. Diagnostic Imaging Centers
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Stool-based
      • 6.1.1.1. Fecal Immunochemical Test (FIT)
      • 6.1.1.2. Fecal Occult Blood Test (FOBT)
      • 6.1.1.3. Stool-DNA Test
    • 6.1.2. Colonoscopy
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By End-user
    • 6.2.1. Hospitals & Clinics
    • 6.2.2. Clinical Laboratories
    • 6.2.3. Diagnostic Imaging Centers
    • 6.2.4. Others
  • 6.3. Market Analysis - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Stool-based
      • 7.1.1.1. Fecal Immunochemical Test (FIT)
      • 7.1.1.2. Fecal Occult Blood Test (FOBT)
      • 7.1.1.3. Stool-DNA Test
    • 7.1.2. Colonoscopy
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By End-user
    • 7.2.1. Hospitals & Clinics
    • 7.2.2. Clinical Laboratories
    • 7.2.3. Diagnostic Imaging Centers
    • 7.2.4. Others
  • 7.3. Market Analysis - By Country/Sub-region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia pacific Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Stool-based
      • 8.1.1.1. Fecal Immunochemical Test (FIT)
      • 8.1.1.2. Fecal Occult Blood Test (FOBT)
      • 8.1.1.3. Stool-DNA Test
    • 8.1.2. Colonoscopy
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By End-user
    • 8.2.1. Hospitals & Clinics
    • 8.2.2. Clinical Laboratories
    • 8.2.3. Diagnostic Imaging Centers
    • 8.2.4. Others
  • 8.3. Market Analysis - By Country/Sub-region
    • 8.3.1. China
    • 8.3.2. India
    • 8.3.3. Japan
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Stool-based
      • 9.1.1.1. Fecal Immunochemical Test (FIT)
      • 9.1.1.2. Fecal Occult Blood Test (FOBT)
      • 9.1.1.3. Stool-DNA Test
    • 9.1.2. Colonoscopy
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By End-user
    • 9.2.1. Hospitals & Clinics
    • 9.2.2. Clinical Laboratories
    • 9.2.3. Diagnostic Imaging Centers
    • 9.2.4. Others
  • 9.3. Market Analysis - By Country/Sub-region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Stool-based
      • 10.1.1.1. Fecal Immunochemical Test (FIT)
      • 10.1.1.2. Fecal Occult Blood Test (FOBT)
      • 10.1.1.3. Stool-DNA Test
    • 10.1.2. Colonoscopy
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By End-user
    • 10.2.1. Hospitals & Clinics
    • 10.2.2. Clinical Laboratories
    • 10.2.3. Diagnostic Imaging Centers
    • 10.2.4. Others
  • 10.3. Market Analysis - By Country/Sub-region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Company Share Analysis for Stool-based Tests, 2025
  • 11.2. Company Share Analysis for Colonoscopes, 2025
  • 11.3. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.3.1. NOVIGENIX SA
    • 11.3.2. EIKEN CHEMICAL CO., LTD.
    • 11.3.3. Clinical Genomics Technologies Pty Ltd.
    • 11.3.4. Exact Sciences Corporation
    • 11.3.5. Epigenomics AG
    • 11.3.6. bioMerieux, Inc.
    • 11.3.7. OLYMPUS CORPORATION
    • 11.3.8. KARL STORZ SE & Co. KG
    • 11.3.9. FUJIFILM Holdings America Corporation

List of Tables

  • Table 01: Global Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Test Type, 2021-2034
  • Table 02: Global Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Stool-based, 2021-2034
  • Table 03: Global Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By End-user, 2021-2034
  • Table 04: Global Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 05: North America Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Test Type, 2021-2034
  • Table 06: North America Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Stool-based, 2021-2034
  • Table 07: North America Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By End-user, 2021-2034
  • Table 08: North America Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 09: Europe Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Test Type, 2021-2034
  • Table 10: Europe Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Stool-based, 2021-2034
  • Table 11: Europe Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By End-user, 2021-2034
  • Table 12: Europe Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
  • Table 13: Asia Pacific Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Test Type, 2021-2034
  • Table 14: Asia Pacific Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Stool-based, 2021-2034
  • Table 15: Asia Pacific Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By End-user, 2021-2034
  • Table 16: Asia Pacific Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
  • Table 17: Latin America Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Test Type, 2021-2034
  • Table 18: Latin America Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Stool-based, 2021-2034
  • Table 19: Latin America Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By End-user, 2021-2034
  • Table 20: Latin America Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
  • Table 21: Middle East & Africa Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Test Type, 2021-2034
  • Table 22: Middle East & Africa Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Stool-based, 2021-2034
  • Table 23: Middle East & Africa Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By End-user, 2021-2034
  • Table 24: Middle East & Africa Colorectal Cancer Screening Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034

List of Figures

  • Figure 01: Global Colorectal Cancer Screening Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Colorectal Cancer Screening Market Value Share (%), By Test Type, 2025 & 2034
  • Figure 03: Global Colorectal Cancer Screening Market Value Share (%), By End-user, 2025 & 2034
  • Figure 04: Global CRO Market Value Share (%), By Region, 2025 & 2034
  • Figure 05: North America Colorectal Cancer Screening Market Value (USD billion), by Test Type, 2025 & 2034
  • Figure 06: North America Colorectal Cancer Screening Market Value Share (%), by Test Type, 2025
  • Figure 07: North America Colorectal Cancer Screening Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 08: North America Colorectal Cancer Screening Market Value Share (%), by End-user, 2025
  • Figure 09: North America Colorectal Cancer Screening Market Value (USD billion), by Country, 2025 & 2034
  • Figure 10: North America Colorectal Cancer Screening Market Value Share (%), by Country, 2025
  • Figure 11: Europe Colorectal Cancer Screening Market Value (USD billion), by Test Type, 2025 & 2034
  • Figure 12: Europe Colorectal Cancer Screening Market Value Share (%), by Test Type, 2025
  • Figure 13: Europe Colorectal Cancer Screening Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 14: Europe Colorectal Cancer Screening Market Value Share (%), by End-user, 2025
  • Figure 15: Europe Colorectal Cancer Screening Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 16: Europe Colorectal Cancer Screening Market Value Share (%), by Country/Sub-region, 2025
  • Figure 17: Asia Pacific Colorectal Cancer Screening Market Value (USD billion), by Test Type, 2025 & 2034
  • Figure 18: Asia Pacific Colorectal Cancer Screening Market Value Share (%), by Test Type, 2025
  • Figure 19: Asia Pacific Colorectal Cancer Screening Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 20: Asia Pacific Colorectal Cancer Screening Market Value Share (%), by End-user, 2025
  • Figure 21: Asia Pacific Colorectal Cancer Screening Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Colorectal Cancer Screening Market Value Share (%), by Country/Sub-region, 2025
  • Figure 23: Latin America Colorectal Cancer Screening Market Value (USD billion), by Test Type, 2025 & 2034
  • Figure 24: Latin America Colorectal Cancer Screening Market Value Share (%), by Test Type, 2021
  • Figure 25: Latin America Colorectal Cancer Screening Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 26: Latin America Colorectal Cancer Screening Market Value Share (%), by End-user, 2025
  • Figure 27: Latin America Colorectal Cancer Screening Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 28: Latin America Colorectal Cancer Screening Market Value Share (%), by Country/Sub-region, 2025
  • Figure 29: Middle East & Africa Colorectal Cancer Screening Market Value Share (%), by Test Type, 2025
  • Figure 30: Middle East & Africa Colorectal Cancer Screening Market Value (USD billion), by Test Type, 2025 & 2034
  • Figure 31: Middle East & Africa Colorectal Cancer Screening Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 32: Middle East & Africa Colorectal Cancer Screening Market Value Share (%), by End-user, 2025
  • Figure 33: Middle East & Africa Colorectal Cancer Screening Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Colorectal Cancer Screening Market Value Share (%), by Country/Sub-region, 2025
  • Figure 35: Global Market Share Analysis for Stool-based Tests, By Company, 2025
  • Figure 36: Global Market Share Analysis for Colonoscopes, By Company, 2025